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Summary 
The effects of treatment with a somatostatin analog (Sandostatin, SMS201-995) were investigated in female 
rats with dimethylbenzanthracene(DMBA)-induced rat mammary tumors. A 3-week treatment was per- 
formed using sandostatin, the LHRH-agonist buserelin alone, or buserelin in combination with sandostatin. 
Twice daily sandostatin treatment was performed with dosages of 0.05/xg, 0.2/xg, 1/xg, 5/zg, and 20/zg. 
Buserelin was used in a 2 x 5 ~g/day dosage. 
The combined results from six different experiments show that the various dosages of sandostatin caused 
no tumor growth inhibition. Somatostatin receptors could not be demonstrated in these mammary tumors. 
Sandostatin treatment by daily injections did not suppress levels of growth hormone, prolactin, or epidermal 
growth factor-like activities. Estrogen (ER) and progesterone (PgR) receptor contents of the mammary 
tumors were not changed. In contrast, buserelin treatment caused highly significant tumor remission. The 
combined treatment with sandostatin and buserelin did not alter the treatment results obtained after 
treatment with buserelin alone. 
In conclusion, sandostatin treatment inthis tumor model had no direct growth inhibitory effect and did not 
cause an endocrine inhibition of mammary tumor growth. However, these results do not exclude antitumor 
effects in human breast cancer in view of the presence of somatostatin receptors in approximately 20-45% of 
human tumors, besides possible different endocrine effects. 
Introduction 
Endocrine treatment of metastatic breast cancer is 
aimed at decreasing plasma concentrations of 
growth stimulatory hormones or factors, or at an- 
tagonizing the biological effects of these hormones 
and factors directly. The involvement of prolactin 
(PRL) and growth hormone (GH) in growth regu- 
lation of human breast cancer cells is still unclear, 
although numerous experimental data obtained 
with rodents support he contention that PRL is 
important in growth and development of their 
mammary tumors [e.g. 1-3]. The binding of human 
GH to the lactogenic receptor of human breast 
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cancer cells in vitro and in vivo may also cause 
growth stimulatory effects [4-7]. The observation 
of increased plasma levels of GH and PRL in breast 
cancer patients [8] may therefore be associated 
with a poorer prognosis compared to patients with 
low hormone levels, as described for GH in pros- 
tate cancer patients [9]. 
Furthermore, GH can increase plasma levels and 
local production of insulin-like growth factor-1 
(IGF-1 or somatomedin C) [10-14]. IGF-1 and es- 
tradiol (E2) are the most potent growth stimulatory 
agents for human breast cancer cells in vitro (for a 
review, see ref. 15). IGF-1 and epidermal growth 
factor (EGF) appear to be autocrine and paracrine 
growth factors for human breast cancer cells [15]. 
Recently, significant levels of IGF-1 receptors were 
demonstrated in more than 90% of human primary 
breast umors [16-19]. Therefore, inhibition of GH 
secretion (and possibly that of IGF-1 and EGF) by 
administration of somatostatin a d its analogs may 
be a means for inhibiting breast cancer growth. 
We found that somatostatin receptors are pre- 
sent in 15-19% of primary breast umor specimens 
[19, 20]. Moreover, we have previously described 
the presence of somatostatin receptors in MCF-7 
human breast cancer cells, and the growth inhib- 
ition of these cells caused by sandostatin [21]. The 
results from two first experiments with rat DMBA- 
induced mammary tumors suggested in vivo 
growth inhibition caused by sandostatin, besides 
additive inhibitory effects of sandostatin and the 
LHRH-agonist buserelin [22]. Combined treat- 
ment with buserelin and sandostatin was studied to 
find out whether the addition of sandostatin might 
improve the tumor remission observed after buse- 
relin treatment alone [e.g. 23]. 
Therefore, we have studied more extensively the 
possible direct and indirect (endocrine) growth in- 
hibitory effects of chronic sandostatin treatment of 
female rats bearing mammary tumors, as a single 
agent or in combination with buserelin. 
Materials and methods 
Female rats of the Sprague-Dawley strain were 
obtained from the Zentralinstitut fur Versuchstier- 
zucht, Hannover, F.R.G. Rats were kept four to a 
cage under controlled light conditions (light on: 
8:00 AM; light off: 7:00 PM) on wood shavings and 
received standard ry pellets (Hope Farms, Woer- 
den, The Netherlands) and tap water ad libitum. 
Hormonal agent solutions 
The somatostatin analog sandostatin (SMS201- 
995) was kindly supplied by Sandoz Ltd., Basel, 
Switzerland, in a stock solution of 0.1 mg/ml. The 
LHRH-agonist buserelin was kindly provided by 
Hoechst A.G., Frankfurt am Main, F.R.G., in a 
stock solution of lmg/ml. Work solutions were 
made by dilution of the stock solutions with 0.15 M 
NaC1. Twice-daily subcutaneous injections of 
sandostatin or buserelin solution were adminis- 
tered in a volume of 100/zl around 9:00AM and 
5:00 PM. Control animals received aily injections 
of 100/zl saline. Final daily dosages per rat were: 
for sandostatin 2 x 0.05/zg, 2 x 0.2/xg, 2 x 1/zg, 
2 x 5~g and 2 x 20/zg; for buserelin 2 x 5/zg (i.e. 
40/zg/kg/day). The highest sandostatin dosage 
used was that described by Lamberts et al. [24]. In 
view of the desensitization reported by them, we 
decided to use lower sandostatin dosages to try to 
circumvent possible desensitization phenomena. 
Combined treatment with sandostatin and busere- 
lin involved separate injections of either hormonal 
agent solution, at distant loci on the back of the rat. 
Tumor induction 
Dimethylbenzanthracene (DMBA, Fluka, Basel, 
Switzerland) was dissolved in olive oil at a concen- 
tration of 10mg/ml. The solution obtained was 
stored in the dark. Induction of mammary tumors 
was performed with 2 intragastric administrations 
of 1 ml of DMBA-solution given with a 7-day in- 
terval to 54--61 day old rats [25]. 
Start of treatments 
Animals were palpated twice weekly to detect he 
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presence of mammary tumors. In total, six differ- 
ent experiments were performed. An overview of 
the experimental treatments as well as the number 
of rats used in the different reatment groups in the 
separate xperiments is presented inTable 1. It was 
impossible to collect data from all rats for each 
parameter for several reasons: untimely death of 
some rats, lack of enough tumor tissue after treat- 
ment, or insufficient amount of blood plasma. 
Treatment began when all rats had palpable tumors 
(105-115 days of age). In studying treatment effects 
on growth of these rat mammary tumors, we have 
found that some tumors may regress and some 
remain stable while other tumors progress, all on 
the same rat, and to some extent even in control 
rats. Therefore, we decided to use the total tumor 
load per rat to compare the treatment results on 
tumor growth. Rats were anaesthetized with dieth- 
yl ether, and the size of the individual tumors was 
measured with calipers and calculated as the prod- 
uct of the two largest perpendicular diameters. For 
each rat, the sum of the individual tumor areas was 
taken as the tumor load of the animal. Rats were 
divided between control and treatment groups (7- 
11 rats per group; equal numbers in the different 
groups in an individual experiment) in such a way 
that the same average tumor load was obtained in 
each group. 
End of treatments 
After treatment for 3 weeks, the tumor load was 
estimated again in anaesthetized rats. The next 
day, the last injections were given around 9:00 
AM, and the animals were killed by decapitation 
without diethyl ether anaesthesia. Rats were killed 
one by one taking rats from the different reatment 
groups in succession. Blood was collected in hepa- 
rinized tubes and in tubes with EDTA-solution. 
Plasma was stored at - 20 ° C until assay for GH, 
PRL, luteinizing hormone (LH), follicle stimulat- 
ing hormone (FSH), E2, insulin, and EGF-like ac- 
tivities. Tumor tissue was collected and stored at 
- 70 ° C until assay for estrogen (ER) and proges- 
terone receptor (PgR). Finally, the weights of the 
pituitary and adrenal glands, and of the ovaries, 
uterus, and pancreas, were recorded. 
Steroid receptor and somatostatin receptor assays 
Assay of cytosolic ER and PgR were performed by 
multiple-point Scatchard analysis, according to the 
procedures recommended by the EORTC for the 
measurement of ER and PgR in the cytosol of 
human breast tumor biopsies [26]. Somatostatin 
receptors were measured by autoradiography on
Table 1. Overview of the experimental reatment groups and the number of rats used in the separate experiments 
Treatment Experiment umber Total number 
of rats 
1 2 3 4 5 6 
Control 5 
Sandostatin: 
2 × 0.05~g 
2× 0.2/zg 
2× ltzg 5 
2 × 5/~g 7 
2 × 20 ~g 8 
Buserelin: 
2x 5tzg 7 
Plus sandostatin: 
2 × 0.2/zg 
2× ltzg 
2 × 20/zg 7 
Total number of rats: 39 
7 8 7 10 8 45 
- 8 7 - 8 23 
- 8 7 - 8 23 
7 8 7 - - 27 
7 - - - 7 21 
8 - 7 - - 23 
8 6 - 11 - 32 
- - - 10  - 10  
- 8 - 11  - 19 
8 . . . .  15 
45 46 35 42 31 238 
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Fig. 1. Box and whisker plot of the effects on relative mammary tumor load after different endocrine treatments for 3 weeks with various 
dosages of sandostatin (denoted on the x-axis), with buserelin (2 × 5/xg), and different combinations of buserelin and sandostatin. C = 
control. Relative tumor load (%) of a rat in a certain treatment group is defined as the ratio of its tumor load at the end of treatment (in 
mm 2) and the average tumor load of the group as a whole (in mm 2) at the start of treatment, and multiplied by 100. The boxes denote the 
interquartile range (from 25-75%) of the results obtained. The horizontal line in the box denotes the median group value. Small circles 
denote outliers. The number of rats used to make this Figure are denoted in the boxes. Initial tumor load = 100%. 
10/zm cryostat sections of the tumor tissue as de- 
scribed for other endocrine tumors [27, 28]. Two 
iodinated somatostatin analogs were used as radio- 
ligands, the Tyr 3 analog of SMS201-995, code- 
named 204-090, [H-(D)Phe-Cys-Tyr-(D)Trp-Lys- 
Thr-Cys-Thr-(ol)], as well as the SS-28 derivative 
[Leu 8, (D)Trp 22, Tyr25]-SS-28 (LTT-SS-28). Both 
analogs have been shown to specifically label soma- 
tostatin receptors [29]. 
Plasma hormone and growth factor assays 
GH and PRL were assayed by radioimmunoassay 
[24]. Assays of LH and FSH were performed as 
described by Welschen et al. [30]. Results are ex- 
pressed in terms of the standards LH RP-1 and FSH 
RP-1 from the NIAMD. E2 was assayed with kits 
obtained from Diagnostic Products Corporation, 
Los Angeles CA, USA. Assay of insulin was per- 
formed with a specific radioimmunoassay using a 
commercially available kit from Incstar, Stillwater, 
Minnesota, U.S.A. EGF-like activities were as- 
sayed by radioreceptor assay after acid-ethanol ex- 
traction of the plasma, using human placental 
membranes as receptor source [18]. 
Statistical evaluation of results 
The treatment effects of sandostatin and buserelin 
were analysed with ANOVA (analysis of variance) 
on the pooled data of the 6 experiments. In the 
ANOVA the experiment umber was included as a 
nominal variable (6 levels) to correct for systematic 
differences between the experiments. For most of 
the endpoints tatistically significant differences 
between experiments were found. This implied 
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that inclusion of this factor in the ANOVA was 
required in order to obtain unbiased estimates of 
the treatment effects of sandostatin ( ominal varia- 
ble with 6 levels: 0/zg, 2 x 0.05/~g, 2 × 0.2/xg, 2 × 
1/zg, 2 x 5/zg, 2 x 20/.~g) and buserelin (nominal 
variable with 2 levels: 0/zg, 2 x 5/zg). In case of a 
very skewed istribution of an endpoint, as was the 
case with most of the plasma hormone levels, alo- 
garithmic transformation r a square root trans- 
formation was performed inorder to obtain a more 
symmetrically distributed variable. The trans- 
formed variable was used in the ANOVA. 
significant difference in tumor load between the 
groups treated with the different sandostatin dos- 
ages and control (ANOVA, P = 0.39). In contrast, 
the effect of buserelin treatment (average tumor 
remission of approx. 60%) was highly significant 
(P< 0.0001). Tumor remission after combined 
treatment with buserelin and three sandostatin 
dosages was not statistically different from that 
resulting from treatment with buserelin alone. 
Effects on all other parameters 
Results 
Effects of treatments on tumor growth 
The relative ffects of chronic treatment with vari- 
ous dosages of sandostatin, with or without busere- 
lin, on rat mammary tumor load are shown in Fig. 
1. Sandostatin treatment caused no inhibition of 
mammary tumor growth. There was no statistically 
ANOVA showed that treatment with buserelin 
(with or without sandostatin) had a strong and 
statistically highly significant effect on almost all of 
the endpoints studied (Table 2). No effect could be 
demonstrated on GH, EGF-like activities, or on 
the weights of the pituitary and the pancreas. Buse- 
relin treatment resulted in a decrease in tumor 
load, ER, PgR, PRL, E2, and the weight of the 
ovaries and the uterus, besides an increase in LH, 
FSH, insulin, and the weight of the adrenals. Be- 
Table 2. Combined results of sandostatin and buserelin treatment on various parameters 
Parameter Combined results from Combined results from Effect of Effect of 
all animals treated* all buserelin treated sandostatin 1 buserelin z 
without buserelin (n = 162) animals (n = 76) (P-value) (P-value) 
Relative tumor load (%) 194 ___ 117 (137) 39 + 40 (60) 0.51 < 0.0001 
ER (fmol/mg) 118 + 55 (95) 61 + 49 (27) 0.73 < 0.0001 
PgR (fmol/mg) 359 + 276 (94) 28 + 27 (23) 0.90 < 0.0001 
GH (/zg/ml) 40 + 41 (118) 29 + 33 (43) 0.97 0.11 
PRL (/zg/ml) 135 + 119 (118) 44 + 35 (43) 0.19 < 0.0001 
LH (ng/ml) 34 + 50 (109) 179 + 255 (41) 0.60 < 0.0001 
FSH (ng/ml) 101 + 63 (113) 367 + 250 (43) 0.55 < 0.0001 
E2 (pmol/l) 61 + 44 (115) 42 + 23 (42) 0.0023 < 0.02 
Insulin (mUd) 11 + 5 (118) 13 + 4 (43) 0.14 <0.0001 
EGF-like activities (ng/ml) 24 + 19 (91) 29 + 14 (29) 0.88 0.86 
Pituitary (mg) 15 + 3 (159) 16 + 2 (72) 0.38 0.88 
Adrenals (mg) 59 + 12 (160) 73 + 16 (75) 0.14 <0.0001 
Ovaries (mg) 133 + 32 (162) 100 + 26 (75) 0.61 <0.0001 
Uterus (mg) 480 + 233 (161) 235 + 51 (75) 0.71 < 0.0001 
Pancreas (mg) 1686 + 336 (87) 1470 + 145 (7) 0.68 0.80 
Results are means + S.D. (n). * control animals included. 1F-test (ANOVA) for the effect of sandostatin corrected for differences 
between experiments; restricted to animals treated without buserelin. 2F-test (ANOVA) for the effect of buserelin corrected for 
differences between experiments and sandostatin dosages. 3 cf. Results ection. 
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Fig. 2. Lack of somatostatin receptors in a DMBA-induced rat 
mammary tumor. A: Hematoxylin-eosin stained section. B: 
Autoradiogram showing total binding of 125I-[Leu s, D-Trp 22, 
TyrZS]-SS-28. C: Autoradiogram showing non-specific binding 
(in the presence of 10 -6 M SS-28). Exposure time: 1 week using 
[aH]-LKB-film (LKB, Rockville, MD., U.S.A.). Bar = 1 ram. 
cause of these strong effects of buserelin, and as the 
majority of the animals were treated without buse- 
relin, the effect of sandostatin was tested restricted 
to the animals treated without buserelin. For none 
of the endpoints (except for E2) was there a statisti- 
cally significant difference between the 6 sandosta- 
tin treatment level groups (control included) (Ta- 
ble 2). The P-values in the table have not been 
corrected for multiple testing. The sandostatin ef- 
fect on E2 might be due merely to chance fluctu- 
ation, in view of the fact that a test for trend was not 
significant, i.e. there was no evidence for a monot- 
onic relation between the dosage of sandostatin 
and the mean value of E2. 
Somatostatin receptors 
No receptors for somatostatin could be demon- 
strated in any of 7 tumors investigated (Fig. 2). 
Discussion 
In contrast to our preliminary observations of in- 
hibitory effects of sandostatin treatment on growth 
of DMBA-induced rat mammary tumors I22], the 
present results obtained in a more elaborate in vivo 
study in female rats showed that sandostatin treat- 
ment did not result in growth inhibition f these 
mammary tumors. For most of the endpoints in- 
vestigated statistically significant differences be- 
tween the six experiments were found, but after 
inclusion of the experiment umber to correct for 
systematic differences between the experiments, 
no significant effects on tumor growth were deter- 
mined. 
The absence of somatostatin receptors in this 
tumor model makes it unlikely for direct growth 
inhibitory effects to occur. This is in contrast to our 
observations of inhibitory effects of somatostatin 
analogs on growth of MCF-7 breast cancer cells, 
which do contain somatostatin receptors [21]. Fur- 
thermore, chronic treatment with the different 
sandostatin dosages was unable to suppress plasma 
levels of hormones and growth factors of interest, 
i.e. GH, PRL, insulin, and EGF-like activities. 
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This phenomenon might be explained by the devel- 
opment of pituitary desensitization by down-regu- 
lation of pituitary somatostatin receptors [24], or 
by missing short-term endocrine ffects, since all 
animals received their last injections early in the 
morning whereas actual killing of these animals 
occurred uring the day. 
It is difficult o explain the significant decrease in
plasma E2 levels. This might be due to chance fluc- 
tuation, in view of the absence of a monotonic 
relation between the dosages of sandostatin and 
the mean values of E2, and because of the absence 
of a significant effect on uterus weight. On the 
other hand, somatostatin has been reported to in- 
hibit gonadotropin secretion in response to admin- 
istration of LHRH in normal men [31] and men- 
struating women [32]. A dissociation between the 
effects on LHRH-induced LH and FSH secretion 
was observed, showing only a significantly de- 
creased LH secretion [32]. Furthermore, Schally 
and Redding [33] reported significantly (p = 0.05) 
decreased testes weights and plasma testosterone 
levels in rats with Dunning prostate tumors treated 
with microcapsules containing the somatostatin 
analog RC-160. These effects on pituitary-gonadal 
function by somatostatin (analogs) might be ex- 
plained by effects at the level of the hypothalamus 
involving catecholamine s cretion [32], and/or by 
direct effects on the gonads [33]. 
Our results are not in agreement with those re- 
ported by other investigators using other experi- 
mental mammary tumor models [12, 13, 34, 35]. 
Administration of a somatostatin a alog has result- 
ed in regression of nitrosomethylurea-induced rat 
mammary carcinoma [34], as well as regression of 
both MT/W9A rat mammary adenocarcinomas 
[13] and MXT mouse mammary carcinomas [35]. 
The different results obtained may be due to: 1. the 
different tumor models used; 2. differences innum- 
bers of animals investigated; 3. the presence or 
absence of somatostatin receptors; 4. the different 
somatostatin analogs used [36]; 5. differences in 
dosages; 6. different modes of administration. 
Treatment with somatostatin analogs may cause 
different endocrine ffects in the various models. 
As in our present study, the number of animals and 
experiments used might influence definite conclu- 
sions. Of paramount importance might be the pres- 
ence of somatostatin receptors required for direct 
growth inhibitory effects. Schally's group demon- 
strated somatostatin receptors in MXT mouse 
mammary carcinoma [35], while we could not dem- 
onstrate these receptors in the DMBA-induced 
mammary tumors. In their experiments, the micro- 
capsules containing the somatostatin analog 
RC-160 liberated 25/xg per day, a dose not differ- 
ent from the highest sandostatin dose in the present 
study. In a transplantable pancreatic tumor model 
we observed no difference in antitumor efficacy of 
equal dosages of RC-160 and sandostatin, with 
both drugs administered by daily injections [37]. 
Therefore, besides the presence of somatostatin 
receptors in their tumor model, the better esults 
reported by Szende et al. [35] might also be ex- 
plained by the mode of drug administration (micro- 
capsules vs. daily injections). Continuous adminis- 
tration of hormone analogs by implants [23] or 
microcapsule formulations [35] proved to be more 
effective than daily injections, as also concluded by 
Szende et al. [35]. In fact, with respect o LHRH 
analogs, we found increased plasma gonadotropin 
levels after treatment with buserelin injections, 
whereas decreased levels were caused by implants 
[23]. Also, a delayed release formulation of the 
somatostatin analog RC-160 appeared more inhib- 
itory towards PRL secretion than i.v. injection of 
the drug [38]. 
Regarding human breast cancers, direct growth 
inhibitory effects of somatostatin analogs are pos- 
sible in view of the presence of somatostatin recep- 
tors in one-sixth up to one-half of tumor samples. 
In continuation of our initial report [39], we have 
found somatostatin receptors in 15% of 110 human 
primary breast tumors by autoradiography [19]. 
This percentage is higher, when fresh and larger 
tumor specimens are used [40]. Papotti et al. [41] 
demonstrated somatostatin receptors in 17% of 100 
breast umors, and observed a significant relation- 
ship with expression of neuroendocrine markers. 
Fekete et al. [42] found somatostatin receptors in 
even 36% of 178 biopsy samples by biochemical 
methods. In our experience, patients with somatos- 
tatin receptor-positive breast umors have a better 
prognosis than patients with somatostatin recep- 
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tor -negat ive tumors [19]. Ant i tumor  effects of 
sandostat in  t reatment  on growth of human breast  
cancer cells have been demonst ra ted  in vitro [21] 
and in nude mice [43]. In pat ients  with metastat ic  
breast  cancer signif icant endocr ine effects have 
been demonst ra ted  ue to chronic sandostat in 
t reatment ,  suggesting also the possibi l i ty of indi- 
rect endocr ine inhibit ion of tumor  growth [44, 45, 
46]. However ,  thus far, the ant i tumor  effects in 
these two phase I I  studies were disappoint ing.  
Manni  et al. [44, 45] observed a tumor  response in 
only 1 out of 10 pat ients,  whereas Vennin et al. [46] 
observed stable disease for longer  than three 
months in only 3 out  of 14 evaluable patients.  These 
relat ively poor  results might be expla ined by the 
fact that  all pat ients  were heavi ly p ret reated  and 
that other  growth st imulatory hormones  were not 
antagonized.  Therefore ,  for more  definite conclu- 
sions on the value of somatostat in  analog traeat-  
ment  in breast  cancer we need more  ( randomized)  
trials. 
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